ICU Medical/$ICUI
1D1W1MYTD1Y5YMAX
Capital at risk
About ICU Medical
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
- Ticker
- $ICUI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 13,000
- Headquarters
- San Clemente, United States
- Website
- www.icumed.com
ICU Medical Metrics
BasicAdvanced
$3.9B
130.65
$1.20
0.76
-
Price and volume
Market cap
$3.9B
Beta
0.76
52-week high
$192.85
52-week low
$112.50
Average daily volume
298K
Financial strength
Current ratio
2.43
Quick ratio
0.996
Long term debt to equity
58.221
Total debt to equity
59.817
Interest coverage (TTM)
1.52%
Profitability
EBITDA (TTM)
326.124
Gross margin (TTM)
38.26%
Net profit margin (TTM)
1.39%
Operating margin (TTM)
5.78%
Effective tax rate (TTM)
3,574.48%
Revenue per employee (TTM)
$170,000
Management effectiveness
Return on assets (TTM)
1.93%
Return on equity (TTM)
1.41%
Valuation
Price to earnings (TTM)
130.648
Price to revenue (TTM)
1.805
Price to book
1.83
Price to tangible book (TTM)
39.4
Price to free cash flow (TTM)
26.91
Free cash flow yield (TTM)
3.72%
Free cash flow per share (TTM)
5.844
Growth
Revenue change (TTM)
-8.97%
Earnings per share change (TTM)
-179.79%
3-year revenue growth (CAGR)
-1.99%
10-year revenue growth (CAGR)
19.59%
3-year earnings per share growth (CAGR)
-15.87%
10-year earnings per share growth (CAGR)
-9.75%
What the Analysts think about ICU Medical
Analyst ratings (Buy, Hold, Sell) for ICU Medical stock.
Analyst projections of the future price of ICU Medical stock.
Bulls say / Bears say
Non-GAAP organic revenue increased 6% year-over-year in Q2 2026, excluding the impact of the IV Solutions divestiture and foreign currency translation, demonstrating robust underlying demand across core businesses (GlobeNewswire).
GAAP gross margin expanded to 43% in Q2 2026 from 38% a year earlier, reflecting operational efficiencies and synergy realization from recent acquisitions (GlobeNewswire).
The company raised its full-year 2026 adjusted EPS guidance from a range of USD 7.75–8.45 to USD 8.60–9.00 and adjusted EBITDA guidance to USD 415–435 million, underscoring management’s confidence in sustained margin expansion and cash flow generation (Company Press Release).
ICU Medical’s Q2 GAAP net income fell 46% year-over-year to USD 19.1 million, driving diluted EPS down to USD 0.76 and highlighting volatility in profitability under GAAP accounting (Bitget News).
As of June 30, 2026, ICU Medical carried USD 1.231 billion of long-term debt against only USD 298.3 million of cash and equivalents, resulting in elevated net leverage that could constrain future capital allocation and M&A flexibility (SEC 10-Q).
FDA has required additional verification testing for the Medfusion 5000 syringe pump, delaying its clearance timeline and posing a risk to the timing of new product revenue in the infusion systems segment (The Motley Fool).
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2026.
ICU Medical Financial Performance
Revenues and expenses
ICU Medical Earnings Performance
Company profitability
Upcoming events
No upcoming events
ICU Medical News
AllArticlesVideos
Funds containing ICU Medical
AllUSDGBPEUR
Fund name | Fund size | $ICUI weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.23% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.23% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.13% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.12% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.12% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.